The AstraZeneca Covid-19 vaccine, which has an average 70% effectiveness against the coronavirus, is ineffective against the South African variant. According to information from the first study that directly compares immunized people with those who did not face the new Sa varietyrs-CoV-2, the drug from Oxford has its effectiveness reduced to 10% against the South African strain.
To obtain the results, the researchers repeated the phase 3 study of the immunizer in South Africa, now that the 'B.1.351' variant is dominant in the country. A group of about 900 people received two doses of the Astrazeneca vaccine and the other, also from 900 people, took a placebo.
The groups were observed in the following weeks. According to the research results, among those who received the placebo, 20 out of 714 people became infected and had mild and moderate forms of covid-19. The same ineffectiveness was shown among those vaccinated, found that 19 out of 750 people had the same symptoms of the disease.
The study was done by scientists at Oxford University and AstraZeneca, who developed the vaccine. In the coming months, similar studies will be carried out at various locations on the planet to ensure that immunizers remain effective against new variants of the coronavirus.
- Covid-19: Brazil has 2.438 deaths in the last 24 hours; total exceeds 292 thousand
- Astrazeneca: scientists find link between vaccine and clot formation
- Meditating to survive in the pandemic: apps facilitate mental relaxation
- Without vaccines, it is difficult to schedule vaccination, experts say
Source: O Estado de São Paulo Newspaper
Have you watched our new videos on YouTube? Subscribe to our channel!